---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-011324"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2022-06-08T23:59:59+00:00"
generated_at: "2026-06-25T03:45:30.304194+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Director Thomas F. Kearns to resign from FibroGen Board effective June 16, 2022

## Summary
- Thomas F. Kearns, Jr. notified resignation from the Board effective June 16, 2022.
- Resignation not due to any disagreement with FibroGen's operations, policies or practices.
- Kearns served since 1996, including as Chair, Lead Independent Director, and committee chairs.

## SEC filing metadata
- accession: 0000950170-22-011324
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2022-06-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017022011324/0000950170-22-011324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017022011324/fgen-20220605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-011324
- JSON: https://secwatch.observer/filing/0000950170-22-011324.json
- Plain text: https://secwatch.observer/filing/0000950170-22-011324.txt

## Key facts
- Executive change
  Thomas F. Kearns, Jr. resigned as Director at KYNTRA BIO, INC..
  - Action: resigned
  - Role: Director
  source text: On June 5, 2022, Thomas F. Kearns, Jr. notified us of his resignation from the Board of Directors (the “Board”) of FibroGen, Inc. (“FibroGen”) effective June 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017022011324/0000950170-22-011324-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.